Current status of multidisciplinary treatment of advanced gastric cancer;Estado actual del tratamiento multidisciplinario del cáncer gástrico avanzado

Cirugia Espanola

Volumn 74, Issue 2, 2003, Pages 69-76

  Calpena, Rafael ^a,b   Javier Lacueva, Francisco ^a,b   Oliver, Israel ^a,b   Cansado, Pilar ^a   Pérez, Francisco ^a   Costa, David ^a   Compañ, Antonio F ^b   Teresa Pérez, María ^b  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^b MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

Author keywords

Chemotherapy; Follow up; Gastric carcinoma; Lymphadenectomies; Prognostic factors; Recurrence

Indexed keywords

EID: 84896694083     PISSN: 0009739X     EISSN: 1578147X     Source Type: Journal    
DOI: 10.1016/S0009-739X(03)72191-5     Document Type: Review

References (82)

1. Karpeh M.S., Kelsen D.P., Tepper J.E. Cancer of the stomach. Cancer. Principles and oractice of oncology. 6th ed 2001, 1092-1126. Lippincott Williams and Wilkins, Philadelphia. V. De Vita, S. Hellman, S.A. Rosenberg (Eds.).
2. Martínez C., Peris R., Sánchez M.J. Epidemiología descriptiva del cáncer en España. Libro blanco de la oncología en España. 3a ed 2002, 583-592. FESEO, Madrid.
3. Wanebo H.J., Kennedy B.J., Chmiel J., Steele G., Winchester D., Osteen R. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg 1993, 218:583-592.
4. Siewert J.R., Bötcher K., Roder J.R., Busch R., Hermanek P., Meyer H.J. Prognostic relevance of systematic lymph node dissection in gastric carcinoma. Br J Surg 1993, 80:1015-1018.
5. Bonenkamp J.J., Hermans J., Sasako M., Van de Velde C.J.H. for the Dutch Gastric Cancer Group. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999, 340:908-914.
6. Sasako M. Risk factors for surgical treatment in the Dutch gastric cancer trial. Br J Surg 1997, 84:1567-1571.
7. Nakamura K., Ueyama T., Yao T., Xuan Z.X., Ambe K., Adachi Y., et al. Pathology and prognosis of gastric carcinoma. Findings in 10,000 patients who underwent primary gastrectomy. Cancer 1992, 70:1030-1037.
8. Compañ A.F., Medrano J., Calpena R., Diego M., Lacueva F.J., Serrano P., et al. Gastric carcinoma: study of the most eminent prognostic factors. Eur J Surg Oncol 1993, 19:553-558.
9. Bollschweiler E., Boettcher K., Hoelscher A.H., Sasako M., Kinoshita T., Maruyama K., et al. Is the prognosis for Japanese and German patients whith gastric cancer really different?. Cancer 1993, 71:2918-2925.
10. Allgayer H., Heiss M.M., Schildberg F.W. Prognostic factors in gastric cancer. Br J Surg 1997, 84:1651-1664.
11. Maruyama K. The most important prognostic factors for gastric cancer patients. A study using univariate and multivariate analysis. Scand J Gastroenterol 1987, 22(Suppl 133):63-68.
12. Bormann R. Geschwuelste des Magens und Duodenum. Handbuch der Spezieller Pathologischen Anatomie und Histologie. Vol. 4 1926, Julius Sringer, Berlin. F. Henke, D. Lubarsch (Eds.).
13. Lauren P. The two histologic main types of gastric carcinoma: diffuse and so-called intestinal type carcinoma: an attempt at a histochemical classification. Acta Pathol Microbiol Scand 1965, 64:31-49.
14. Adachi Y., Yasuda K., Inomata M., Sato K., Shiraishi N., Kitano S. Pathology and prognosis of gastric carcinoma. Well versus poorly differentiated type. Cancer 2000, 89:1418-1424.
15. Boku T., Nakane V., Minoura T., Takada H., Yamamura M., Hioki K., et al. Prognostic significance of serosal invasion and free intraperitoneal cancer cels in gastric cancer. Br J Surg 1990, 17:436-439.
16. Maruyama K., Gunven P., Okabayashi K., Sasako M., Kinoshita T. Lymph node metastases of gastric cancer. General pattern in 1931 patients. Ann Surg 1989, 210:596-602.
17. Bonenkamp J.J., Songun I., Hermans J., Van de Velde C.J.H. Prognostic value of positive cytology findings from abdominal washings in patients with gastric cancer. Br J Surg 1996, 83:672-674.
18. Suzuki T., Ochiai T., Hayashi H., Mori S., Shimada H., Isono K. Peritoneal lavage cytology findings as prognostic factor for gastric cancer. Sem Surg Oncol 1999, 17:103-107.
19. Bando E., Yonemura Y., Takeshita Y., Taniguchi K., Yasui T., Yoshimitsu Y., et al. Intraoperative lavage for cytological examination in 1297 patients with gastric carcinoma. Am J Surg 1999, 178:256-262.
20. Yonemura Y., Fujimura T., Ninomiya I., Kim B.S., Bandou E., Sawa T., et al. Prediction of peritoneal micrometastasis by peritoneal lavaged cytology and Reverse Transcriptase-Polymerase Chain Reaction for matrix metalloproteinase-7 mRNA. Clin Cancer Res 2001, 7:1647-1653.
21. Kodera Y., Nakanishi H., Seiji I., Yamamura Y., Kanemitsu Y., Shimizu Y., et al. Quantitative detection of disseminated free cancer cells in peritoneal washes with Real-Time Reverse Transcriptase-Polymerase Chain Reaction. A sensitive predictor outcome for patients with gastric carcinoma. Ann Surg 2002, 235:499-506.
22. Siewert J.R., Bötcher K., Stein H.J., Roder J.D. Relevant prognostic factors in gastric cancer. Ten-year results of the German Gastric Cancer Study. Ann Surg 1998, 4:449-461.
23. Noguchi Y., Imada T., Matsumoto A. Radical surgery for gastric cancer: a review of the Japanese experience. Cancer 1989, 64:2053-2062.
24. Ochiai T., Sasako M., Mizuno S., Kinoshita T., Takayama T., Kosuge T., et al. Hepatic resection for metastatic tumors from gastric cancer: analysis of prognostic factors. Br J Surg 1994, 81:1175-1178.
25. Yasui W., Yokozaki H., Fujimoto J., Naka K., Kuniyasu H., Tahara E. Genetic and epigenetic alterations in multistep carcinogenesis of the stomach. J Gastroenterol 2000, 35(Suppl XII):111-115.
26. Nekarda H., Schmitt M., Ulm K., Wenninger A., Vogelsang H., Becker K., et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 1994, 54:2900-2907.
27. Heiss M.M., Babic R., Allgayer H., Gruetzner U., Jauch K.W., Loehrs U., et al. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol 1995, 13:2084-2093.
28. Yonemura Y., Endo Y., Fujita H., Fushida S., Bandou E., Taniguchi K., et al. Role of MMP-7 in the formation of peritoneal dissemination in gastric cancer. Gastric Cancer 2000, 3:63-70.
29. Yonemura Y., Endou Y., Kimura K., Fushida S., Bandou E., Taniguchi K., et al. Inverse expression of S-100A4 and E-cadherin is associated with metastatic potential in gastric cancer. Clin Cancer Res 2000, 6:4234-4242.
30. Maehara Y., Kabashima A., Koga T., Tokunaga E., Takeuchi Y., Kakeji Y. Vascular invasion and potential for tumor angiogenesis and metastasis in gastric carcinoma. Surgery 2000, 128:408-416.
31. Allgayer H., Babic R., Gruetzner K.U., Tarabichi A., Schildberg F.W., Heiss M.M. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 2000, 18:2201-2209.
32. Joypaul B.V., Hopwood D., Newman E.L., Qureshi S., Grant A., Ogston S.A., et al. The prognostic significance of the accumulation of p53 tumour- supressor gene protein in gastric adenocarcinoma. Br J Cancer 1994, 69:943-946.
33. Gabbert H.E., Müller W., Schneiders A., Meier S., Hommel G. The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer 1995, 76:720-726.
34. Victorzon M., Nordling S., Haglund C., Lundin J., Roberts P.J. Expression of p53 protein as a prognostic factor in patients with gastric cancer. Eur J Cancer 1996, 32:215-220.
35. Poremba C., Yandell D.W., Huang Q., Little J.B., Mellin W., Schmid K.W., et al. Frequency and spectrum of p53 mutations in gastric cancer: a molecular genetic and immunohistochemical study. Virchows Arch 1995, 426:447-455.
36. Tolbert D.M., Noffsinger A.F., Miller M.A., De Voe G.V., Stemmermann G.M., Macdonald J.S., et al. p53 immunoreactivity and single strand conformational polymorphism analysis often fail to predict p53 mutational status. Mod Pathol 1999, 12:54-60.
37. Lowe S.W., Ruley H.E., Jacks T., Housman D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993, 74:957-967.
38. Chin K.V., Ueda, Pastan I., Gottesman M.M. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992, 255:459-462.
39. Lacueva F.J., Calpena R., Medrano J., Teruel A., Mayol M.J., Graells M.L., et al. Changes in P-glycoprotein expression in gastric carcinoma with respect to distant gastric mucosa may be influenced by p53. Cancer 2000, 89:21-28.
40. Bellamy W.T. P-glycoprotein and multidrug resistance. Annu Rev Pharmacol Toxicol 1996, 36:161-183.
41. Cascinu S., Graziano F., Del Ferro E., Staccioli M.P., Ligi M., Carnevali A., et al. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer 1998, 83:1917-1922.
42. Lenz H.J., Leichman G., Danenberg K.D., Danenberg P.V., Groshen S., Cohen H., et al. Thymidylate Synthase mRNA level in adenocarcinoma of the stomach: a predictor for primay tumor response and overall survival. J Clin Oncol 1995, 14:176-182.
43. Metzger R., Leichman C.G., Danenberg K.D., Danenberg P.V., Lenz H.J., Hayashi K., et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predictor response and survival for gastric cancer patients receiving combination cisplatin and fluoracil chemotherapy. J Clin Oncol 1998, 16:309-316.
44. Bozzetti F., Marubini E., Bonfanti G., Miceli R., Piano C., Crosse N., et al. Total versus subtotal gastrectomy. Surgical morbidity and mortality rates in a multicenter Italian randomized trial. Ann Surg 1997, 226:613-620.
45. Cuschieri A., Fayers P., Fielding J., Craven J., Bancewicz J., Joypaul V., et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MCR randomized controlled surgical trial. Lancet 1996, 347:995-999.
46. Brennan M.F. Lymph-node dissection for gastric cancer. N Engl J Med 1999, 340:956-957.
47. Mc Near G., Vandenberg H., Donn F.Y. A critical evaluation of subtotal gastrectomy for cure of cancer of the stomach. Ann Surg 1951, 134:2-7.
48. Brennan M.F., Karpeh M.S. Surgery for gastric cancer: the American view. Semin Oncol 1996, 23:352-359.
49. Soga J., Ohyama S., Miyashita K., Suzuki T., Nashimoto A., Tanaka O., et al. A statistical evaluation of advancement in gastric cancer surgery with special reference to the significance of lymphadenectomy for cure. World J Surg 1988, 12:398-405.
50. Fugii M., Sasaki J., Nakashima T. State of the art in the treatment of gastric cancer: from the 71st Japanese Gastric Cancer Congress. Gastric Cancer 1999, 2:151-157.
51. Pacelli F., Doglietto G.B., Bellantone R., Alfieri S., Sgadari A., Crucitti F. Extensive versus limited lymph node dissection for gastric cancer: A comparative study of 320 patients. Br J Surg 1993, 80:1153-1156.
52. Cuschieri A., Weeden Fielding S., Bancewicz J., Craven J., Joypaul V., et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MCR randomized surgical trial. Br J Cancer 1999, 79:1522-1530.
53. Bunt A.M.G., Hermans J., Smit V.T., Van de Velde C.J.H., Fleuren G.J., Bruijn J.A. Surgical/pathologic stage migration confounds comparisons of gastric cancer survival rates between Japan and Western countries. J Clin Oncol 1995, 13:19-25.
54. Maruyama K., Sasko M., Kinoshita T., Sano T., Katai H. Surgical treatment for gastric cancer: the Japanese approach. Semin Oncol 1996, 23:360-368.
55. Park J.G., Gazdar A.F., Kim Y., Choi B.I., Song I.S., Kim N.K., et al. Gastric cancer in Korea: experience at the Seoul National University Hospital. Management of gastric cancer 1991, 285-305. Kluwer Academic, Norwell. P.H. Sugarbaker (Ed.).
56. Roukos D., Paraschou D. Extended lymph node dissection in gastric cancer: standard, selective or unnecesary procedure?. Hepato- Gastroenterol 2000, 47:904-906.
57. Hermans J., Bonenkamp J.J., Boon M.C., Bunt A.M.C., Ohyama S., Sasko M., et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993, 11:1441-1447.
58. Earle C.C., Maroun J.A. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a metaanalysis of randomised trials. Eur J Cancer 1999, 35:1059-1064.
59. Shimada K., Ajani J.A. Adjuvant therapy for gastric carcinoma patients in the past 15 years. A review of western and oriental trials. Cancer 1999, 86:1657-1668.
60. González Moreno S., Sugarbaker P.H. Comprehensive management of resectable gastric cancer: requirement for optimal clearance, containment and perioperative intraperitoneal chemotherapy. Rev Oncol 2000, 3:129-140.
61. Sautner T., Hofbauer F., Depisch D., Schiessel R., Jakesz R. Adjuvant intraperitoneal cisplatin chemotherapydoes not improve long term survival after surgery for advanced gastric cancer. J Clin Oncol 1994, 12:970-974.
62. Hagiwara A., Takahashi T., Kojima O., Saway K., Yamaguchi T., Yamane T., et al. Prophilaxis with carbon absorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet 1992, 339:629-631.
63. Yonemura Y., Ninomiya I., Kaji M., Sugiyama K., Fujimura K., Sawa T., et al. Prophilaxis with intraoperative chemohyperthermia against peritoneal recurrence of gastric cancer. Lancet 1992, 339:629-631.
64. Hamazoe R., Maeta M., Kaibara N. Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Cancer 1994, 73:2048-2052.
65. Fujimoto S., Takahashi M., Mutou T., Kobayashi K., Toyosawa T., Isawa E. Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hiperthermic chemoperfusion combined with surgery. Cancer 1997, 79:884-891.
66. Yu W., Whang I., Chung H.Y., Averbach A., Sugarbaker P.H. Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial. World J Surg 2001, 25:985-990.
67. Cambray M. La radioterapia en el cáncer gástrico. Rev Oncol 2002, 4:289-296.
68. Macdonald J.S., Smalley S.R., Benedetti J., Hundahl S.A., Estes N.C., Stemmermann G.N., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach of the gastroesophageal junction. N Engl J Med 2001, 345:725-730.
69. Averbach A.M., Jacquet P. Strategies to decrease the incidence of intra- abdominal recurrence in resectable gastric cancer. Br J Surg 1996, 83:726-733.
70. Yonemura Y. Mechanisms of the formation of peritoneal dissemination. Peritoneal dissemination. Molecular mechanisms and the latest therapy 1998, 1-46. Maeda Shoten Co Ltd., Kanazawa. Y. Yonemura (Ed.).
71. Gunderson L.L., Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiation Oncology Biol Phys 1982, 8:1-4.
72. Yoo C.H., Noh S.H., Shin D.W., Choi S.H., Min J.S. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000, 87:236-242.
73. Maehara Y., Hasuda S., Koga T., Tokunaga Y., Kakeji Y., Sugimachi K. Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg 2000, 87:353-357.
74. Lacueva F.J., Calpena R., Medrano J., Compan A., Andrada E., Molto M., et al. Follow-up of patients resected for gastric cancer. J Surg Oncol 1995, 60:174-179.
75. Kim K.W., Choi B.I., Han J.K., Kim T.K., Kim A.Y., Lee H.J., et al. Postoperative anatomic and pathologic findings at CT following gastrectomy. Radiographics 2002, 22:323-336.
76. Sohn K.M., Lee J.M., Lee S.Y., Ahn B.Y., Park S.M., Kim K.M. Comparing MR imaging and CT in the staging of gastric carcinoma. AJR 2000, 174:1551-1557.
77. De Potter T., Flamen P., Van Cutsem E., Penninckx F., Filez L., Bormans G., et al. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med 2002, 29:525-529.
78. Stahl A., Ott K., Weber W.A., Fink U., Siewert J.R., Schwaiger M. Correlation of FDG uptake in gastric carcinomas with endoscopic and histopathological findings. J Nucl Med 2001, 42:P78-79.
79. Guadagni F., Roselli M., Amato T., Cosimelli M., Manella E., Perri P., et al. Tumor-associated glycoprotein-72 serum levels complement carcinoembrionic- antigen levels in monitoring patients wih gastrointestinal carcinoma. Cancer 1991, 68:2443-2450.
80. Marrelli D., Pinto E., De Stefano A., Farnetani M., Garosi L., Roviello F. Clinical utility of CEA, CA 19-9 and CA 72-4 in the follow-up of patients with resectable gastric cancer. Am J Surg 2001, 181:16-19.
81. Joypaul B., Browning M., Newman E., Byrne D., Cuschieri A. Comparison of serum CA 72-4 and CA 19-9 levels in gastric cancer patients and correlation with recurrence. Am J Surg 1995, 169:595-599.
82. Nakata B., Hirakawa K., Kato Y., Yamashita Y., Maeda K., Onoda N., et al. Serum CA 125 levels as a predictor of peritoneal dissemination in patients with gastric carcinoma. Cancer 1998, 83:2488-2492.